Navigation Links
arGEN-X Initiates Phase IbStudy of ARGX-111 in Cancer
Date:9/17/2013

BREDA, the Netherlands, and GHENT, Belgium, September 17, 2013 /PRNewswire/ --

SIMPLE Antibody™ with unique mode of action addressing c-Met positive tumors

arGEN-X, a clinical stage human monoclonal antibody therapeutics company, announces today the CTA filing of a first-in-man Phase Ib cancer study with ARGX-111, its second proprietary SIMPLE Antibody™ product to enter the clinic this year.

ARGX-111 is a c-Met-targeting human monoclonal antibody that modulates all known mechanisms of action of the receptor. As well as best-in-class blocking of both ligand dependent and independent signalling through c-Met, ARGX-111 benefits from POTELLIGENT®-enhanced Antibody Dependent Cellular Cytotoxicity (ADCC), which drives the immune system to destroy c-Met positive tumor cells. Owing to this unique combination of therapeutic attributes, ARGX-111 has demonstrated superior therapeutic potential in both solid and hematological malignancies when compared to established biologic and small molecule-based c-Met therapies. ARGX-111  has  been shown to be safe and well-tolerated in non-human primate studies.

The Phase Ib study will enroll patients with tumors that have been pre-screened for over-expression of c-Met. Because of the known role of c-Met activation in promoting the metastatic potential of tumor cells, the study will also document the eradication of those patients' circulating tumor cells (CTCs), which are known to be precursors of advancing disease.

"ARGX-111 has all of the attributes to become the next-generation c-Met inhibitor of choice, given it combines best-in-class blockade of receptor function with enhanced ADCC. With such a compelling therapeutic profile, we are confident that ARGX-111 has the potential both to treat established tumors and to eradicate CTCs before they seed metastases," said Alain Thibault, M.D., Chief Medical Officer at arGEN-X. "ARGX-111 is an excellent example of how our suite of antibody technologies enables us to generate exciting development candidates with multiple modes of action within a single therapeutic entity."

Ahmad Awada, M.D., Ph.D. of the Jules Bordet Institute, Brussels, Belgium, and Principal Investigator of the study, commented further: "The field of c-Met inhibition is one that offers significant promise in the fight against cancer. Therefore, we are very excited to be involved in the first ever clinical trial with ARGX-111, a potentially best-in-class molecule for the treatment of a broad range of solid and hematological cancers."

About the ARGX-111 Phase Ib Trial

The Phase Ib study being undertaken by arGEN-X includes an adaptive dose escalation scheme, to be followed by a safety cohort expansion.  Approximately 35 patients will be enrolled by a consortium of leading academic institutions in Belgium. In addition to traditional clinical and PK endpoints, biomarkers critical to understanding the effect of ARGX-111 on c-Met biology will be researched during the course of the trial.

About arGEN-X - http://www.arGEN-X.com

arGEN-X is a clinical stage human therapeutic antibody company that is rapidly developing a product pipeline using its unique suite of antibody technologies. arGEN-X is creating first and best in class antibody therapeutics with highly differentiated target product profiles. Its therapeutic antibody programs, focused on cancer and autoimmune indications, are designed to deliver tangible benefits to patients with these diseases.

arGEN-X' SIMPLE Antibody™ platform generates an unprecedented diversity of high quality human antibodies, enabling optimal product choice. SIMPLE Antibodies™ are able to address and modulate any disease target, including complex receptors and highly conserved targets often intractable with other antibody technologies. SIMPLE Antibody™ generated leads are further differentiated as products through enhancement of cell killing properties (POTELLIGENT®, licensed from BioWa Inc.) and optimization of circulation time and distribution in the body (NHance™). ArGEN-X is also developing ABDEG™ technology, to potentiate the clearance of disease-causing autoantibodies.

In January 2013, arGEN-X initiated a Phase Ib clinical trial for ARGX-110, its most advanced SIMPLE Antibody™ program modulating CD70 via a unique mode of action in hematological and virally-induced solid tumors. A second CTA for ARGX-111, a novel anti-c-Met antibody to treat diverse solid tumors, is the subject of this press release.

The SIMPLE Antibody™ platform is covered by broad patent claims, enjoys an independent, unencumbered patent position and is free of target gatekeeping restrictions.

SIMPLE stands for Superior Immunodiversity with Minimal Protein Lead Engineering.

arGEN-X™, SIMPLE Antibody™ and NHance™ are deposited trademarks of arGEN-X BV.

For further information, please contact:

Citigate Dewe Rogerson
David Dible
Mark Swallow
Nina Enegren
T: +44(0)207-282-2949/2948/1050
E: david.dible@citigatedr.co.uk

arGEN-X
Tim Van Hauwermeiren, MSc, eMBA
Chief Executive Officer
T: +31-6-122-85-257
E: tim.vh@arGEN-X.com

Alain Thibault, M.D.
Chief Medical Officer
T: +32-471-81-71-24
E: athibault@argen-x.com



'/>"/>
SOURCE arGEN-X
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. arGEN-X Appoints Dr. David L. Lacey to its Supervisory Board
2. arGEN-X Announces Preclinical Development of ARGX-112 for Dermatology
3. arGEN-X Identifies Potent Antibody Antagonists against Complex Chronic Pain Target Nav1.7
4. Asubio Initiates Landmark Clinical Study in Spinal Cord Injury
5. CSL Behring Initiates Study of Subcutaneous Administration of C1-esterase Inhibitor in Patients with Hereditary Angioedema
6. Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia
7. Alder BioPharmaceuticals Inc. Initiates Phase 1 Clinical Study of Antibody Therapeutic Candidate for Treatment of Migraine, ALD403
8. Oncos Therapeutics Initiates Phase I Clinical Study of CGTG-102, an Oncolytic Adenovirus for the Treatment of Solid Tumor Cancers
9. MAQUET Initiates Class I Recall of the FLOW-i Anesthesia System
10. Stryker Initiates Voluntary Product Recall of Modular-Neck Stems
11. Inovio Initiates H1N1 Universal Influenza Vaccine Clinical Trial Targeting Over-65 Population, Which Represents 90% of Flu Deaths
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... 21, 2017 Mass Spectrometer Market: Overview ... This report on mass spectrometer ... prospects of the market globally. The stakeholders of ... the manufacture and commercialization of various mass spectrometer ... planning to enter this market. This report comprises ...
(Date:2/21/2017)... -- Luminex Corporation (NASDAQ: LMNX ) (the "Company") today ... of a quarterly cash dividend to its shareholders, the first ... payable on April 14, 2017 to shareholders of record as ... The board of directors intends for the Company ... holders of its common stock, representing a planned annual dividend ...
(Date:2/21/2017)... Feb. 21, 2017  Global health services company Cigna ... ® for breast reconstruction surgery and Dermacell ... an advanced acellular dermal matrix developed by LifeNet Health ... NVDQ ) "We are proud ... health-care payers to review the growing base of evidentiary ...
Breaking Medicine Technology:
(Date:2/21/2017)... ... ... As recently as 2015, rhinoplasty was one of the Top 5 cosmetic ... patients want to make a change in the appearance of their nose while others ... team at usrhinoplasty.org is expanding its article database to better inform its ...
(Date:2/21/2017)... ... 2017 , ... American Veterinarian™, the premier multimedia provider of ... first bi-monthly issue of 2017 in February. The inaugural issue will offer expert ... , In making the announcement, American Veterinarian™ Publisher Chris Hennessy said, “We ...
(Date:2/21/2017)... San Francisco, California (PRWEB) , ... February 21, ... ... in the world with over 50,000 participants. The connected care demonstration spanned ... Office of the National Coordinator, roughly 30% of providers have no Health Information ...
(Date:2/21/2017)... ... February 21, 2017 , ... Along with Valentine’s Day, February marks ... small changes that can lead to a lifetime of heart health. In addition, ... emergency. , The Athletic Trainers’ Society of New Jersey (ATSNJ) is urging ...
(Date:2/20/2017)... ... 20, 2017 , ... Daily Body Restore, "DBR" a company ... “good” bacteria in the body, announced its Daily Body Restore® supplement is now ... Body Restore® is made with a unique combination of digestive enzymes and probiotics ...
Breaking Medicine News(10 mins):